Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
11.43
Oct 20 • 3:59 PM ET Dollar change+0.61 Percentage change(5.64%)
Aftermarket Close
11.38
Aftermarket • 6:10 PM ET Dollar change-0.05 Percentage change(-0.44%)
Index
RUT
Market Cap
1.89B
Enterprise Value
1.46B
Income
-247.73M
Sales
413.80M
Book/sh
-1.16
Cash/sh
4.36
Employees
749
IPO
Dec 05, 1995
P/E
-
Forward P/E
435.59
PEG
-
P/S
4.56
P/B
-
P/C
2.62
P/FCF
-
EV/EBITDA
-
EV/Sales
3.54
Quick Ratio
2.30
Current Ratio
2.33
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.52
EPS next Y
0.03
EPS next Q
-0.22
EPS this Y
-123.05%
EPS next Y
104.41%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
-17.24% 18.76%
EPS Y/Y TTM
-158.19%
Sales Y/Y TTM
-61.64%
EPS Q/Q
-153.98%
Sales Q/Q
-76.30%
Insider Own
4.97%
Insider Trans
0.00%
Inst Own
65.37%
Inst Trans
0.30%
ROA
-21.62%
ROE
-
ROIC
-241.68%
Gross Margin
78.65%
Oper. Margin
-28.82%
Profit Margin
-59.87%
SMA20
0.01%
SMA50
12.66%
SMA200
24.28%
Trades
Shs Outstand
164.82M
Shs Float
156.76M
52W High
13.39 -14.61%
52W Low
6.20 84.35%
Volatility
9.88% 9.25%
ATR (14)
0.99
RSI (14)
52.41
Beta
2.65
Rel Volume
1.11
Avg Volume
5.87M
Volume
6,510,283
Perf Week
-10.84%
Perf Month
9.80%
Perf Quarter
44.50%
Perf Half Y
34.63%
Perf YTD
70.09%
Perf Year
30.03%
Perf 3Y
77.76%
Perf 5Y
-91.65%
Perf 10Y
-63.60%
Prev Close
10.82
Price
11.43
Change %
5.64%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ruxandra Draghia AkliFormer OfficerMay 27 '26Proposed Sale11.0121,383235,412May 27 04:42 PM
Ruxandra Draghia AkliFormer OfficerMay 07 '26Proposed Sale9.8730,000296,083May 07 05:03 PM
Newton Charles W.DirectorApr 25 '26Option Exercise0.009,52009,520Apr 28 05:00 PM
Shiver John W.DirectorMar 10 '26Option Exercise0.007,94707,947Mar 12 05:00 PM
Kelly James PatrickEVP, CFO and TreasurerMar 07 '26Option Exercise0.0012,2230136,503Mar 09 06:13 PM
Kelly James PatrickEVP, CFO and TreasurerMar 03 '26Option Exercise0.0043,1670145,130Mar 05 06:04 AM
Jacobs John CPresident and CEOMar 03 '26Option Exercise0.00150,1670264,130Mar 05 06:03 AM
O'Hara ElaineEVP, Chief Strategy OfficerMar 03 '26Option Exercise0.0056,3340157,071Mar 05 06:02 AM
Casey Mark JEVP, Chief Legal OfficerMar 03 '26Option Exercise0.0037,5000101,445Mar 05 06:01 AM
Draghia-Akli RuxandraEVP, Research & DevelopmentMar 03 '26Option Exercise0.0026,667034,876Mar 05 06:00 AM
Jacobs John CPresident and CEOMar 01 '26Option Exercise0.0083,3330264,130Mar 03 09:37 PM
Kelly James PatrickEVP, CFO and TreasurerMar 01 '26Option Exercise0.0058,6660130,299Mar 03 09:35 PM
O'Hara ElaineEVP, Chief Strategy OfficerMar 01 '26Option Exercise0.0059,6000111,706Mar 03 09:34 PM
Casey Mark JEVP, Chief Legal OfficerMar 01 '26Option Exercise0.004,000065,159Mar 03 09:33 PM
Jacobs John CPresident and CEOJan 23 '26Option Exercise0.0083,1970219,929Jan 26 07:57 PM
Casey Mark JEVP, Chief Legal OfficerDec 11 '25Option Exercise0.0041,899073,972Dec 15 04:01 PM
Draghia-Akli RuxandraSection 16Nov 11 '25Option Exercise0.0014,257014,257Nov 13 05:23 PM
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
PresidentMr. John Charles Jacobs M.B.A.
Executive VPMr. James Patrick Kelly C.F.A.
J.D.Mr. Mark J. Casey Esq.
Executive VP & Chief Strategy OfficerMs. Elaine O'Hara
Executive VP & COOMr. Richard P. Crowley